Larimar Therapeutics Inc Financials

LRMR

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Larimar Therapeutics Inc (LRMR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 21/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Larimar Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Larimar Therapeutics Inc carries a low D/E ratio of 0.87, meaning only $0.87 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 84/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Larimar Therapeutics Inc's current ratio of 2.19 indicates adequate short-term liquidity, earning a score of 40/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Larimar Therapeutics Inc generates a -212.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -46.9% the prior year.

Piotroski F-Score Weak

1/9

Larimar Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.68x

For every $1 of reported earnings, Larimar Therapeutics Inc generates $0.68 in operating cash flow (-$113.2M OCF vs -$165.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$172.1M

YoY-90.1%

Larimar Therapeutics Inc's EBITDA was -$172.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 90.1% from the prior year.

Net Income

-$165.7M

YoY-105.5%

Larimar Therapeutics Inc reported -$165.7M in net income in fiscal year 2025. This represents a decrease of 105.5% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$113.3M

YoY-59.0%

Larimar Therapeutics Inc generated -$113.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 59.0% from the prior year.

Cash & Debt

$85.4M

YoY+157.1%

5Y CAGR+4.6%

10Y CAGR+9.1%

Larimar Therapeutics Inc held $85.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

83M

YoY+30.2%

5Y CAGR+40.1%

Larimar Therapeutics Inc had 83M shares outstanding in fiscal year 2025. This represents an increase of 30.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-212.2%

YoY-165.3pp

5Y CAGR-164.8pp

10Y CAGR-168.2pp

Larimar Therapeutics Inc's ROE was -212.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 165.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$154.2M

YoY+110.5%

5Y CAGR+37.5%

10Y CAGR+10.9%

Larimar Therapeutics Inc invested $154.2M in research and development in fiscal year 2025. This represents an increase of 110.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$91K

YoY-82.3%

5Y CAGR+8.0%

10Y CAGR-17.1%

Larimar Therapeutics Inc invested $91K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 82.3% from the prior year.

LRMR Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$154.2M+110.5%	$73.3M+164.8%	$27.7M+14.1%	$24.3M-36.8%	$38.4M+22.3%	$31.4M
SG&A Expenses	$18.3M+3.8%	$17.6M+25.0%	$14.1M+14.8%	$12.3M+1.7%	$12.1M+5.9%	$11.4M
Operating Income	-$172.5M-89.8%	-$90.9M-117.7%	-$41.8M-14.3%	-$36.5M+27.6%	-$50.5M-17.9%	-$42.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$165.7M-105.5%	-$80.6M-118.1%	-$36.9M-4.5%	-$35.4M+30.2%	-$50.6M-19.2%	-$42.5M
EPS (Diluted)	N/A	$-1.32-57.1%	$-0.84+38.7%	$-1.37+53.6%	$-2.95+17.4%	$-3.57

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$25.0M	N/A	$44.9M+92.3%	$23.4M-12.0%	$26.6M	N/A	$13.9M-29.3%	$19.7M
SG&A Expenses	$6.1M	N/A	$4.6M+3.3%	$4.4M-4.6%	$4.6M	N/A	$4.3M-11.6%	$4.9M
Operating Income	-$31.1M	N/A	-$49.5M-78.1%	-$27.8M+10.9%	-$31.2M	N/A	-$18.3M+25.8%	-$24.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	$0	$0	N/A	N/A	$0	$0
Net Income	-$29.6M	N/A	-$47.7M-82.2%	-$26.2M+10.6%	-$29.3M	N/A	-$15.5M+28.3%	-$21.6M
EPS (Diluted)	$-0.31	N/A	$-0.61-48.8%	$-0.41+10.9%	$-0.46	N/A	$-0.24+29.4%	$-0.34

LRMR Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$145.8M-27.2%	$200.2M+108.7%	$95.9M-24.1%	$126.4M+60.7%	$78.7M-24.9%	$104.7M
Current Assets	$142.0M-27.3%	$195.3M+116.6%	$90.2M-25.3%	$120.7M+67.2%	$72.2M-26.3%	$98.0M
Cash & Equivalents	$85.4M+157.1%	$33.2M+24.2%	$26.7M-0.3%	$26.8M-61.7%	$70.1M+2.9%	$68.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$67.8M+138.5%	$28.4M+99.9%	$14.2M-8.3%	$15.5M+8.8%	$14.3M-4.9%	$15.0M
Current Liabilities	$64.8M+166.0%	$24.4M+156.2%	$9.5M-11.2%	$10.7M+21.0%	$8.8M-1.6%	$9.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$78.1M-54.6%	$171.8M+110.2%	$81.7M-26.3%	$110.9M+72.2%	$64.4M-28.2%	$89.7M
Retained Earnings	-$434.8M-61.6%	-$269.2M-42.7%	-$188.6M-24.4%	-$151.6M-30.4%	-$116.3M-77.2%	-$65.6M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$208.5M+43.0%	$145.8M-22.2%	$187.3M+24.9%	$150.0M-11.9%	$170.2M-15.0%	$200.2M-8.6%	$219.0M-7.6%	$237.2M
Current Assets	$205.0M+44.3%	$142.0M-22.5%	$183.2M+25.9%	$145.6M-12.0%	$165.5M-15.3%	$195.3M-8.4%	$213.3M-7.7%	$231.1M
Cash & Equivalents	$177.9M+108.3%	$85.4M-5.2%	$90.1M+337.8%	$20.6M-2.6%	$21.1M-36.4%	$33.2M-5.3%	$35.1M+8.5%	$32.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$50.5M-25.5%	$67.8M+40.2%	$48.3M+60.3%	$30.1M+16.3%	$25.9M-8.8%	$28.4M+37.8%	$20.6M-19.9%	$25.8M
Current Liabilities	$47.8M-26.3%	$64.8M+43.6%	$45.1M+69.3%	$26.6M+20.4%	$22.1M-9.1%	$24.4M+49.6%	$16.3M-23.0%	$21.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$158.0M+102.4%	$78.1M-43.8%	$139.0M+16.0%	$119.9M-16.9%	$144.3M-16.0%	$171.8M-13.4%	$198.4M-6.2%	$211.4M
Retained Earnings	-$464.4M-6.8%	-$434.8M-16.8%	-$372.3M-14.7%	-$324.6M-8.8%	-$298.4M-10.9%	-$269.2M-12.0%	-$240.3M-6.9%	-$224.8M

LRMR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$113.2M-60.0%	-$70.8M-111.5%	-$33.5M-21.4%	-$27.6M+34.5%	-$42.1M+0.2%	-$42.2M
Capital Expenditures	$91K-82.3%	$515K+214.0%	$164K+64.0%	$100K-70.0%	$333K+437.1%	$62K
Free Cash Flow	-$113.3M-59.0%	-$71.3M-112.0%	-$33.6M-21.5%	-$27.7M+34.8%	-$42.4M-0.4%	-$42.3M
Investing Cash Flow	$100.3M+217.5%	-$85.4M-356.0%	$33.4M+136.7%	-$91.0M-476.3%	$24.2M+41.4%	$17.1M
Financing Cash Flow	$65.1M-59.8%	$161.9M+539510.0%	$30K-100.0%	$75.3M+278.5%	$19.9M-78.8%	$93.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$44.6M	N/A	N/A	-$19.4M+27.0%	-$26.5M-21.7%	-$21.8M+11.1%	-$24.5M-75.5%	-$14.0M
Capital Expenditures	$49K	$0-100.0%	$23K+21.1%	$19K-61.2%	$49K-72.6%	$179K+188.7%	$62K	N/A
Free Cash Flow	-$44.7M	N/A	N/A	-$19.4M+27.0%	-$26.6M-20.9%	-$22.0M+10.6%	-$24.6M	N/A
Investing Cash Flow	$29.0M	N/A	N/A	$18.8M+30.4%	$14.4M-24.7%	$19.2M-29.6%	$27.3M+143.0%	-$63.5M
Financing Cash Flow	$108.1M	N/A	N/A	N/A	N/A	$36K+20.0%	$30K+109.0%	-$334K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

LRMR Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-212.2%-165.3pp	-46.9%-1.7pp	-45.2%-13.3pp	-31.9%+46.7pp	-78.6%-31.3pp	-47.4%
Return on Assets	-113.6%-73.3pp	-40.3%-1.8pp	-38.5%-10.5pp	-28.0%+36.4pp	-64.4%-23.8pp	-40.6%
Current Ratio	2.19-5.8	8.02-1.5	9.49-1.8	11.28+3.1	8.16-2.7	10.89
Debt-to-Equity	0.87+0.7	0.170.0	0.17+0.0	0.14-0.1	0.22+0.1	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-18.7%	N/A	-34.3%-12.5pp	-21.8%-1.5pp	-20.3%	N/A	-7.8%+2.4pp	-10.2%
Return on Assets	-14.2%	N/A	-25.5%-8.0pp	-17.5%-0.3pp	-17.2%	N/A	-7.1%+2.0pp	-9.1%
Current Ratio	4.29+2.1	2.19-1.9	4.06-1.4	5.46-2.0	7.48-0.5	8.02-5.1	13.10+2.2	10.93
Debt-to-Equity	0.32-0.5	0.87+0.5	0.35+0.1	0.25+0.1	0.18+0.0	0.17+0.1	0.10-0.0	0.12
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Diamedica Therapeutics Inc DMAC

$306.1M

Benitec Biopharm BNTC

$374.1M

Rocket Pharmaceu RCKT

$335.2M

Assembly Bioscie ASMB

$435.8M

Bright Minds Biosciences Inc DRUG

$734.0M

Frequently Asked Questions

Is Larimar Therapeutics Inc profitable?

No, Larimar Therapeutics Inc (LRMR) reported a net income of -$165.7M in fiscal year 2025.

What is Larimar Therapeutics Inc's EBITDA?

Larimar Therapeutics Inc (LRMR) had EBITDA of -$172.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Larimar Therapeutics Inc's return on equity (ROE)?

Larimar Therapeutics Inc (LRMR) has a return on equity of -212.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Larimar Therapeutics Inc's free cash flow?

Larimar Therapeutics Inc (LRMR) generated -$113.3M in free cash flow during fiscal year 2025. This represents a -59.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Larimar Therapeutics Inc's operating cash flow?

Larimar Therapeutics Inc (LRMR) generated -$113.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Larimar Therapeutics Inc's total assets?

Larimar Therapeutics Inc (LRMR) had $145.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Larimar Therapeutics Inc's capital expenditures?

Larimar Therapeutics Inc (LRMR) invested $91K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Larimar Therapeutics Inc spend on research and development?

Larimar Therapeutics Inc (LRMR) invested $154.2M in research and development during fiscal year 2025.

How many shares does Larimar Therapeutics Inc have outstanding?

Larimar Therapeutics Inc (LRMR) had 83M shares outstanding as of fiscal year 2025.

What is Larimar Therapeutics Inc's current ratio?

Larimar Therapeutics Inc (LRMR) had a current ratio of 2.19 as of fiscal year 2025, which is generally considered healthy.

What is Larimar Therapeutics Inc's debt-to-equity ratio?

Larimar Therapeutics Inc (LRMR) had a debt-to-equity ratio of 0.87 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Larimar Therapeutics Inc's return on assets (ROA)?

Larimar Therapeutics Inc (LRMR) had a return on assets of -113.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Larimar Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Larimar Therapeutics Inc (LRMR) had $85.4M in cash against an annual operating cash burn of $113.2M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Larimar Therapeutics Inc's Piotroski F-Score?

Larimar Therapeutics Inc (LRMR) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Larimar Therapeutics Inc's earnings high quality?

Larimar Therapeutics Inc (LRMR) has an earnings quality ratio of 0.68x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Larimar Therapeutics Inc?

Larimar Therapeutics Inc (LRMR) scores 21 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.